Interestingly, the in vitro blockage of LAG-3 by a monoclonal antibody, relatlimab, in CLL patient-derived PBMCs improved NK cell cytotoxicity and the production of IL-2 by conventional T cells [35]. The gene discussed is IL2; the disease is B-cell chronic lymphocytic leukemia.